IL-18 Emerges as a Key Driver of Atopic Dermatitis Severity and Inflammation
A new review reveals IL-18 correlates with AD severity and barrier dysfunction, positioning it as a promising therapeutic target.
Summary
Atopic dermatitis (AD) is a chronic inflammatory skin condition causing itch, barrier breakdown, and immune infiltration. This review highlights IL-18, an IL-1 family cytokine, as a central player in AD pathophysiology. Elevated IL-18 levels in skin and blood track closely with disease severity and type 2 immune responses. Mouse model studies reinforce this link, showing that blocking or knocking out IL-18 reduces AD-like features. The authors synthesize genetic associations, biomarker data, and cellular mechanisms to argue that targeting IL-18 could be a viable new treatment strategy. While promising, the review is based on existing literature, and clinical trials specifically targeting IL-18 in AD are still needed to confirm therapeutic benefit.
Detailed Summary
Atopic dermatitis affects millions worldwide and remains incompletely understood despite major advances in immunology. Current treatments, while effective for some, leave many patients with inadequately controlled disease. Identifying new molecular targets is therefore a priority in dermatology and allergy research.
This 2025 review, published in the Journal of Allergy and Clinical Immunology, focuses on IL-18, a cytokine belonging to the IL-1 family. The authors synthesize available evidence on IL-18's genetic associations, its utility as a biomarker, and its cellular sources within the skin, drawing on human studies and preclinical mouse models.
Key findings indicate that IL-18 levels are elevated in both the skin tissue and serum of AD patients, and these levels positively correlate with disease severity, the degree of type 2 immune activation, and impaired skin barrier function. In mouse models of AD, either neutralizing IL-18 with antibodies or genetically knocking it out reduced AD-like disease features, strengthening the causal argument.
The review also details how IL-18 promotes type 2 immune responses — the dominant immune axis in AD — through specific cellular mechanisms, though the precise pathways remain an active area of investigation. Genetic data further support IL-18's relevance in human AD susceptibility.
The authors conclude that IL-18 represents a compelling therapeutic target. One co-author is affiliated with Novartis, a potential conflict of interest to note. As a review article based on existing literature rather than new experimental data, it cannot establish causation beyond what prior studies support. Dedicated clinical trials targeting IL-18 in AD patients will be essential to validate this therapeutic hypothesis.
Key Findings
- IL-18 levels in skin and serum are elevated in AD and correlate positively with disease severity.
- IL-18 promotes type 2 immune responses, the dominant inflammatory axis in atopic dermatitis.
- Mouse models show that IL-18 neutralization or genetic knockout alleviates AD-like features.
- Genetic associations and biomarker data support a pathophysiological role for IL-18 in human AD.
- Targeting IL-18 is proposed as a promising new therapeutic strategy for atopic dermatitis.
Methodology
This is a narrative review article synthesizing published human studies, genetic association data, biomarker analyses, and preclinical mouse model experiments. No original experimental data were generated by the authors. The review covers IL-18's cellular sources, receptor signaling, and downstream immune effects in the context of AD.
Study Limitations
As a review, the paper cannot establish new causal relationships and is limited by the quality and scope of existing literature. One co-author's affiliation with Novartis introduces a potential conflict of interest regarding therapeutic framing. Clinical trials specifically evaluating IL-18 blockade in AD patients are lacking, leaving the therapeutic hypothesis unvalidated in humans.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.